Clinical trials
Tumor clinical trials
Below are recruiting tumor clinical trials, each written for real people, not researchers. We’re tracking 3,417 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04740398RecruitingPhase 1
CBP-1008 for advanced solid tumors that standard therapy failed
This Phase 1 study tests CBP-1008, a new experimental treatment, in people with advanced solid cancers that either worsened after standard treatment or for which no standard option exists. It may help doctors learn the safest dose and whether it shows signs of benefit in specific tumor types.
Beijing, Beijing MunicipalityAges 18–70 - NCT05244551RecruitingPhase 1
First study drug for advanced cancers with FGFR changes
This early-phase study tests the safety and best dose of ABSK061 in people with advanced solid tumors. It may help people whose cancers have specific FGFR2/3 gene changes, especially urothelial cancer or cholangiocarcinoma.
Dallas, TexasAges 18 years+ - NCT05245058RecruitingEarly Phase 1
SPH5030 for HER2-positive advanced solid tumors
This early-stage study tests SPH5030 tablets in people with HER2-positive advanced solid tumors that have not responded to standard treatment or have no standard option. It aims to see whether the treatment can shrink tumors and is safe enough to move forward.
Hefei, AnhuiAges 18 years+ - NCT05103345RecruitingPhase 1/Phase 2
Injection into tumors to treat advanced solid cancers
This early-phase study tests a medicine called SGN1 given directly into a solid tumor. It’s for people with advanced cancers that have not responded to standard treatment (or don’t have good standard options) and aims to see if the injection is safe and may work.
Guangzhou, GuangdongAges 18–75 - NCT05260385RecruitingPhase 1/Phase 2
Study drug KC1036 for advanced digestive cancers
This early-phase study tests whether KC1036 can treat advanced digestive system cancers that have come back or spread after standard treatment. It may help people by shrinking tumors or slowing growth, and it will also check safety and side effects.
BeijingAges 18–75 - NCT05098197RecruitingEarly Phase 1
Study of TIL cell therapy for advanced liver, bile, or pancreas cancer
This trial studies a treatment called TIL therapy, which uses your own immune cells grown from a tumor sample, to treat advanced cancers of the liver/bile ducts or pancreas. It’s mainly for people whose standard treatments have already failed (or none exist), and who can safely provide tumor tissue for the cell preparation.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT05263479RecruitingPhase 1
Study drug for advanced solid tumors that can’t be treated
This Phase 1 trial tests HS-20089 in people with advanced solid cancers that have limited standard treatment options. It focuses on safety and early signs of whether the drug can shrink tumors or control them.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT05217693RecruitingPhase 1
First study drug BB-1705 for advanced solid tumors
This Phase 1 trial tests BB-1705 in people with advanced or metastatic (spread) solid tumors that cannot be removed with surgery. It mainly focuses on safety and how the drug behaves in the body, and may offer an option for patients when standard treatments have not worked.
BeijingAges 18–78 - NCT05142423RecruitingPhase 1/Phase 2
First study of AK109 plus AK104 for advanced solid cancers
This Phase 1/2 trial tests a combination of two immune-targeting drugs (AK109 and AK104) in people with advanced solid tumors that can’t be treated with standard options, or where standard treatment didn’t work or wasn’t tolerated. It aims to find safe dosing and whether the treatment can shrink tumors or control the disease.
Hangzhou, ZhejiangAges 18–75 - NCT05436093Recruiting
PET scan using a tumor-targeting probe in solid tumors
This trial studies whether a special PET scan probe that targets CLDN18.2 can help show solid tumors in the body. If you have a solid tumor that can be measured on scan, you may be invited to have imaging with the probe.
Beijing, Beijing MunicipalityAges 18–75 - NCT04928612RecruitingPhase 1
CBP-1018 for advanced cancers that no standard treatment helped
This early-phase study tests CBP-1018 in people with advanced solid tumors, such as prostate, kidney, or certain lung cancers. It aims to see how the drug works and whether it’s safe enough to continue studying.
Guangzhou, GuangdongAges 18 years+ - NCT05068583Recruiting
Testing liquid blood samples in children with certain cancers
This trial studies “liquid biopsies,” which are blood tests, to help learn about specific cancers in children. It may help doctors monitor cancer and guide treatment using less invasive tests.
Los Angeles, CaliforniaAges 6 months+ - NCT04762641RecruitingPhase 1
First-dose safety study of ABL503 for advanced cancers
This Phase 1 trial tests the safety and side effects of ABL503 and finds the best dose to study next. It is for people with advanced cancer that is growing despite prior treatment options.
Duarte, CaliforniaAges 18 years+ - NCT04775485RecruitingPhase 2
Targeted medicine for children with certain brain or solid tumors
This Phase 2 study tests tovorafenib, a targeted cancer medicine, in children and young adults whose tumors have specific BRAF or RAF changes. It is for cancers that have come back or grown despite previous treatment, with measurable signs on scans.
San Francisco, CaliforniaAges 6 months–25 years - NCT06730659RecruitingPhase 1
CHT101 for CD70-positive advanced solid tumors
This study tests a new drug called CHT101 for people with advanced solid tumors that have a specific protein (CD70) on the cancer cells. It may be an option if standard treatments have already been tried and failed.
TianjinAges 18–70 - NCT05718895RecruitingPhase 1
ATG-022 for advanced solid tumors that have stopped responding
This early-phase study tests ATG-022 in adults with advanced or metastatic solid cancers that have progressed on standard treatment, cannot use standard treatment, or have no standard option. It may help by targeting cancer cells differently, and participation includes close monitoring and likely a biopsy.
AdelaideAges 18 years+ - NCT04643418RecruitingPhase 1/Phase 2
Study drug for advanced solid tumors you can’t remove
This trial tests MPB-1734, a new study drug, in adults with advanced solid tumors that can’t be removed and for which standard treatment has stopped working. It aims to find out how safe it is and whether it can shrink or control the cancer.
TaipeiAges 18 years+ - NCT05098184RecruitingEarly Phase 1
Study TIL treatment for advanced melanoma using harvested tumor cells
This early-phase trial tests GC101 TIL, a treatment made from your own melanoma tumor cells, for advanced melanoma. It may help the immune system better fight the cancer after standard treatments have already stopped working or if none are available.
ShanghaiAges 18–75 - NCT05036226RecruitingPhase 1/Phase 2
COAST therapy for advanced prostate or other solid tumors
This early-phase trial tests the COAST therapy approach in people with advanced solid tumor cancers or advanced prostate cancer that has continued to grow despite standard treatments. The study aims to see how well the treatment works and whether it is safe enough to continue studying.
Charleston, South CarolinaAges 18 years+ - NCT05477849RecruitingPhase 1
Study drug for people with advanced solid tumors
This Phase 1 trial tests the safety and early effects of VG2025 in people with advanced solid cancers that have stopped responding to standard treatments. It’s mainly looking for side effects and how the body processes the drug, and it may offer a new option when other treatments haven’t worked.
Hangzhou, ZhejiangAges 18–75 - NCT04423185RecruitingPhase 2
Precision medicine trial for rare advanced solid tumors
This study tests targeted drugs or immunotherapy based on the genetic features of your tumor. It may help people with rare, advanced cancers whose disease has progressed after standard treatment options.
BeijingAges 18 years+ - NCT05405595RecruitingPhase 1/Phase 2
Study drug with pembrolizumab for advanced solid tumors
This early-stage trial tests a new investigational drug (ADG126) combined with pembrolizumab in people with advanced or metastatic solid tumors. It aims to find a safe dose and see whether the combination can shrink tumors.
Scottsdale, ArizonaAges 18 years+ - NCT04282083Recruiting
Registry for adults with confirmed digestive neuroendocrine tumors
This is a registry study that collects medical information from adults with neuroendocrine tumors (NETs) that start in the digestive organs. It helps researchers understand these cancers better and may support future studies.
Rozzano, MilanAges 18 years+ - NCT03772561RecruitingPhase 1
Testing AZD5363, olaparib, and durvalumab for advanced solid cancers
This Phase 1 trial tests a combination of three medicines to shrink or control advanced solid tumors that are progressing or no standard options exist. It mainly focuses on safety and early signs of how well the treatment works.
Singapore, SingaporeAges 21–99
Hear when a new Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for tumor?
- Yes. Clin2 currently lists 3,417 recruiting tumor studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a tumor trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a tumor trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.